Diagnostic assessment of DNA aneuploidy and modified risk model for 202 patients recruited from September 2017 to December 2018 constituted the test set
| Group | General OPMD (n = 194) | OPMD concomitant OSCC (n = 8) | Diagnostic accuracy (95% confidence interval) |
|---|---|---|---|
| DI ≥ 3.5 | False positive (n = 16) | True positive (n = 5) | Sensitivity = 62.5% (30.4%–86.5%) |
| DI < 3.5 | True negative (n = 178) | False negative (n = 3) | Specificity = 91.8% (86.9%–94.9%) |
| Risk model (score ≥ 4) | False positive (n = 23) | True positive (n = 8) | Sensitivity = 100% |
| Risk model (score < 4) | True negative (n = 171) | False negative (n = 0) | Specificity = 88.1% (82.9%–92.0%) |
DI, DNA index; OPMD, oral potentially malignant disorder; OSCC, oral squamous cell carcinoma.